- Home
- ENTA vs SRV Comparison
ENTA vs SRV Comparison
Compare ENTA & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- SRV
- Stock Information
- Founded
- ENTA 1995
- SRV 2007
- Country
- ENTA United States
- SRV United States
- Employees
- ENTA N/A
- SRV N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- SRV Finance Companies
- Sector
- ENTA Health Care
- SRV Finance
- Exchange
- ENTA Nasdaq
- SRV Nasdaq
- Market Cap
- ENTA 164.6M
- SRV 195.1M
- IPO Year
- ENTA 2013
- SRV N/A
- Fundamental
- Price
- ENTA $8.28
- SRV $44.33
- Analyst Decision
- ENTA Strong Buy
- SRV
- Analyst Count
- ENTA 4
- SRV 0
- Target Price
- ENTA $22.25
- SRV N/A
- AVG Volume (30 Days)
- ENTA 158.9K
- SRV 33.9K
- Earning Date
- ENTA 08-11-2025
- SRV 01-01-0001
- Dividend Yield
- ENTA N/A
- SRV 13.38%
- EPS Growth
- ENTA N/A
- SRV N/A
- EPS
- ENTA N/A
- SRV N/A
- Revenue
- ENTA $64,806,000.00
- SRV N/A
- Revenue This Year
- ENTA N/A
- SRV N/A
- Revenue Next Year
- ENTA $1.65
- SRV N/A
- P/E Ratio
- ENTA N/A
- SRV N/A
- Revenue Growth
- ENTA N/A
- SRV N/A
- 52 Week Low
- ENTA $4.09
- SRV $30.73
- 52 Week High
- ENTA $13.37
- SRV $44.30
- Technical
- Relative Strength Index (RSI)
- ENTA 49.11
- SRV 64.13
- Support Level
- ENTA $8.25
- SRV $43.67
- Resistance Level
- ENTA $9.08
- SRV $44.51
- Average True Range (ATR)
- ENTA 0.44
- SRV 0.50
- MACD
- ENTA -0.08
- SRV 0.04
- Stochastic Oscillator
- ENTA 3.78
- SRV 89.35
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.